We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Can Predict Breast Cancer Risk

By LabMedica International staff writers
Posted on 17 May 2012
A blood test that spots changes in a specific gene could reveal a woman's risk for breast cancer years before the disease has a chance to develop. More...

Women with the highest level of methylation on one area gene were more likely to develop cancer than those with the lowest level of methylation because high levels of methylation signal high levels of DNA flaws.

Scientists from Imperial College (London, UK) analyzed blood samples from breast cancer patients and women without breast cancer. The samples from the breast cancer patients were collected an average of three years before they were diagnosed with the disease. Samples were from a case-control study derived from a cohort of high-risk breast cancer families and nested case-control studies in two prospective cohorts. Bisulfite pyrosequencing was used to quantify methylation from 640 incident cases of invasive breast cancer and 741 controls.

The objective was to find out if the alteration of ataxia telangiectasia mutated (ATM) genes by a process called methylation could predict a woman's breast cancer risk. The analysis of the blood samples identified alterations in the ATM gene that did not occur because of having active cancer or cancer treatments. This result was particularly pronounced in blood samples taken from women under the age of 60.
This blood test used in combination with other breast cancer risk assessment tools such as genetic testing and risk factor profiling, could help identify women at higher risk. This early warning could be used to monitor these patients and one day perhaps even prevent them from developing breast cancer. The study identifies a significant association between breast cancer risk and gene-specific methylation in leucocyte DNA measured in prediagnostic blood samples from cases in prospective cohorts and using pyrosequencing, which is a highly quantitative method.

James Flanagan, PhD, the senior author of the study said, "We know that genetic variation contributes to a person's risk of disease. With this new study, we can now also say that epigenetic variation, or differences in how genes are modified, also has a role. So far, we have found alterations in one small region of a gene that appear to associate with risk of disease, and so the next step with this epigenetic research is a genome-wide approach to try and find all the associated genes" The study was published on May 1, 2012, in the journal Cancer Research.

Related Links:
Imperial College



Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.